Egis Pharmaceuticals PLC DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Hungarian Pharma Giants May Begin Uzbekistan Production

24 Jun 2025

// PRESS RELEASE

Egis & the University of Szeged Expand Their Cooperation

05 Mar 2025

// PRESS RELEASE

Our project aimed at developing oncological active ingredients

24 Feb 2025

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPhI Korea

Attending

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

7 Corporate Content #SupplierSpotlight, 1 Data Compilation #PharmaFlow, 29 News #PharmaBuzz

media
7 Corporate Content #SupplierSpotlight
1 Data Compilation #PharmaFlow
29 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

53 All APIs, 2 USDMF, 17 CEP/COS, 5 JDMF, 4 KDMF, 2 NDC API, 2 VMF, 44 Listed APIs

53 All APIs
2 USDMF
17 CEP/COS
5 JDMF
4 KDMF
2 NDC API
2 VMF
44 Listed APIs

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

87 FDF Dossiers, 87 Listed Dossiers

87 FDF Dossiers
87 Listed Dossiers

KEY PRODUCTS

Abemaciclib, Atorvastatin, Chlorpromazine Hydrochloride, Dapagliflozin, Levomepromazine Maleate, Osimertinib Mesylate, Promethazine Hydrochloride, Ramipril, Ribociclib, Sacubitril-Valsartan

Abemaciclib
Atorvastatin
Chlorpromazine Hydrochloride
Dapagliflozin
Levomepromazine Maleate
Osimertinib Mesylate
Promethazine Hydrochloride
Ramipril
Ribociclib
Sacubitril-Valsartan

SERVICES

API Manufacturing, API & Drug Product Development

pharmaServices
API Manufacturing
API & Drug Product Development
- 5 API Development

KEY SERVICES

CDMO for Small Molecules, Manufacturing of Intermediates & APIs, Highly Potent API Manufacturing, CDMO for Intermediates & APIs

CDMO for Small Molecules
Manufacturing of Intermediates & APIs
Highly Potent API Manufacturing
CDMO for Intermediates & APIs

INSPECTIONS & REGISTRATIONS

7 FDA, 25 EDQM, 1 GDUFA

inspections
7 FDA
25 EDQM
1 GDUFA

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

About

Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its products under Egis’ brand names in 18 countries. In total, the company’s APIs & finished products reach 100 countries. Egis’ focus lies on treating diseases of cardiovascular & central nervous systems; however, it also provides modern treatment solutions in the fields of diabetology, dermatology & wound care. Our research and development activities focus on high-quality, value-added branded generic products. From 2023, Egis offers its CDMO & CMO services as well.

CPhI KoreaCPhI Korea

Industry Trade Show

Attending

26-28 August, 2025

COEX, Seoul, Korea
ChemOutsourcingChemOutsourcing

Industry Trade Show

Attending

08-10 September, 2025

Parsippany NJ, Hilton
CPhI WW FrankfurtCPhI WW Frankfurt

Industry Trade Show

Booth #9.2A26

28-30 October, 2025

Frankfurt

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Hungary

Address

1106 Budapest, Keresztúri út 30-38

Telephone

+36 18035555

mailbox@egis.hu

Website

https://int.egis.health/home

https://www.linkedin.com/company/egis-pharmaceuticals-plc/

YouTube

http://www.youtube.com/@EgisPharma-rs6qr

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Product List 2025

Open PDF

Upload

Corporate Presentation

Open PDF

Upload

FDF Product List 2025

Open PDF

Upload

API Product List 2025

Open PDF

Upload

APIs Under Development 2025

Pharma Services

GMP Certificate 2024

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord). Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation.